Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Docetaxel
Drug ID BADD_D00699
Description Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel reversibly binds to tubulin with high affinity in a 1:1 stoichiometric ratio
Indications and Usage For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.
Marketing Status Prescription; Discontinued
ATC Code L01CD02
DrugBank ID DB01248
KEGG ID D02165
MeSH ID D000077143
PubChem ID 148124
TTD Drug ID D0O5WP
NDC Product Code 0955-1022; 67457-781; 45963-765; 47335-323; 57884-3042; 66758-050; 43598-611; 43598-258; 54893-0008; 0409-5068; 43598-389; 55150-378; 0955-1020; 72485-214; 0409-0368; 70700-176; 68083-401; 70700-174; 65129-1189; 70121-1223; 65129-1298; 0143-9204; 65129-1141; 47335-895; 0143-9205; 55150-379; 57884-3041; 47335-939; 70121-1222; 70700-175; 0409-4235; 17359-9100; 0409-0367; 16729-267; 68083-400; 68554-0075; 43066-001; 0409-0365; 43066-010; 72485-215; 66758-950; 43598-259; 55150-380; 70747-1004; 68083-399; 70121-1221; 45963-734; 0955-1021; 0409-0366; 43066-006; 43598-610; 72485-216; 57884-3043
Synonyms Docetaxel | Docetaxel Trihydrate | Docetaxol | Docetaxel Hydrate | Taxoltere Metro | RP 56976 | RP-56976 | RP56976 | Taxotere | Docetaxel Anhydrous | N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol | N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol | NSC 628503
Chemical Information
Molecular Formula C43H53NO14
CAS Registry Number 114977-28-5
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O) O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cell deathCaspase-3P42574T57943Not Available
Cell deathApoptosis regulator Bcl-2P10415T31309Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pancytopenia01.03.03.0030.001332%Not Available
Paraesthesia17.02.06.005--
Paraplegia17.01.04.0070.000533%Not Available
Parosmia22.04.03.007; 17.04.04.002--Not Available
Pericardial effusion02.06.01.0020.001332%
Peripheral motor neuropathy17.09.03.004--
Peripheral sensory neuropathy17.09.03.0050.000533%
Pharyngitis07.05.07.004; 22.07.03.004; 11.01.13.003--
Phlebitis12.02.01.002; 24.05.03.0010.001332%
Photopsia17.17.01.006; 06.02.06.004--
Photosensitivity reaction23.03.09.0030.000799%
Platelet count decreased13.01.04.001--
Pleural effusion22.05.02.0020.002931%
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pneumonia aspiration22.01.01.0050.000139%Not Available
Pneumonitis22.01.01.0060.000556%
Pneumothorax22.05.02.0030.000208%
Polyneuropathy17.09.03.0120.000533%Not Available
Presyncope02.01.02.007; 24.06.02.010; 17.02.05.0090.000533%
Productive cough22.02.03.0050.000139%
Prostate cancer metastatic21.04.02.004; 16.25.01.0020.000208%Not Available
Prothrombin level decreased13.01.02.010--Not Available
Prurigo23.03.04.017--Not Available
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary fibrosis22.01.02.006--
Pulmonary hypertension24.08.03.002; 22.06.01.0010.000139%
Pulmonary oedema02.05.02.003; 22.01.03.003--
Pulmonary veno-occlusive disease24.01.06.008; 22.06.03.0030.000533%Not Available
Pyrexia08.05.02.0030.009324%
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 15 Pages